Pulmo BioTech Inc. completes bio-distribution studies
Pulmo BioTech Inc. has announced that its subsidiary, PulmoScience Inc. has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of molecular imaging of the vascular system of the lungs.
Molecular Imaging uses a molecule designed to bond specifically to certain parts of the body. In the case of PulmoBind, the chosen molecule was designed to bond only to the inner walls of the vascular system of the lungs. Because the molecule (code named DFH-12) is tagged with a radionuclide, the integrity of the lung's vascular system can then be imaged using the Gamma Cameras which are typically available in all hospitals with a Nuclear Medicine department.
It is important for diagnostic image quality that the PulmoBind molecule is only retained in the lungs, and we are very pleased to announce that in-vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes after injection with only minor retention (~ 1/10th) in the liver and heart. It is equally important that after imaging the molecule is quickly eliminated from the body and further bio-distribution studies have show that after 240 minutes the majority of the injected molecules have been eliminated through the kidneys and bladder.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Laryngomalacia

What determines whether we become overweight? - More than just lifestyle and genes: New factor influencing excess body weight discovered
Rescue protein gives doomed cells a stay of 'execution'
Recombination hotspot stacks the DNA deck in finding a new diabetes susceptibility gene
Mouthwash
New view of the heartbeat
Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca

The aging brain: protein mapping furnishes new insights - Researchers at LMU and the SyNergy Cluster of Excellence have analyzed how the proteome of specific brain cells changes as we age

Poor heart health predicts premature brain ageing - Multiple risk factors for a prematurely ageing brain identified
